Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04729543 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer

Study acronym: MC2TCR
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 4, 2023 (before its estimated December 20, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Dec 20, 2022 to Dec 20, 2024v3
  2. Primary completion date: Oct 20, 2022 to Dec 20, 2022v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Single-centre, first-in-man phase I/II trial to demonstrate safety and efficacy of MAGE-C2/HLA-A2 TCR T cells (MC2 TCR T cells) in advanced melanoma (MEL) and head-and-neck carcinoma (HNSCC).
Trial Details
NCT Number NCT04729543
Lead Sponsor Erasmus Medical Center
Collaborators: Ludwig Institute for Cancer Research, Dutch Cancer Society, Stichting Coolsingel Rotterdam grant, Jan Ivo Stichting grant
Conditions Melanoma, Melanoma, Uveal, Head and Neck Cancer
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov